Accuray (NASDAQ:ARAY) Upgraded by StockNews.com to "Buy" Rating

Accuray (NASDAQ:ARAY - Get Free Report) was upgraded by research analysts at StockNews.com from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Monday.

Accuray Price Performance

Shares of Accuray stock traded down $0.05 during trading on Monday, hitting $2.24. 473,033 shares of the company were exchanged, compared to its average volume of 796,198. The company has a quick ratio of 0.87, a current ratio of 1.62 and a debt-to-equity ratio of 3.51. Accuray has a fifty-two week low of $1.40 and a fifty-two week high of $2.95. The stock has a market capitalization of $229.83 million, a price-to-earnings ratio of -44.70 and a beta of 1.51. The firm has a 50 day moving average price of $2.13 and a 200 day moving average price of $1.98.

Accuray (NASDAQ:ARAY - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.03. Accuray had a negative return on equity of 9.75% and a negative net margin of 0.96%. On average, equities analysts expect that Accuray will post 0.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Foundry Partners LLC grew its stake in shares of Accuray by 51.3% during the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider's stock valued at $3,937,000 after buying an additional 741,900 shares during the period. State Street Corp grew its stake in shares of Accuray by 3.8% during the 3rd quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider's stock valued at $3,410,000 after buying an additional 70,008 shares during the period. Barclays PLC grew its stake in shares of Accuray by 97.9% during the 3rd quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider's stock valued at $380,000 after buying an additional 104,310 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Accuray by 1,650.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 146,384 shares of the medical equipment provider's stock valued at $263,000 after buying an additional 138,022 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Accuray by 489.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider's stock valued at $500,000 after buying an additional 230,695 shares during the period. 64.08% of the stock is currently owned by institutional investors and hedge funds.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.